# OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

> **NCT02654587** · PHASE3 · TERMINATED · sponsor: **OSE Immunotherapeutics** · enrollment: 219 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** OSE2101
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02654587
- **Lead sponsor:** OSE Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-12
- **Primary completion:** 2021-01-15
- **Final completion:** 2021-01-15
- **Target enrollment:** 219 (ACTUAL)
- **Why stopped:** due to COVID-19
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654587, "OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02654587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*